NCT02788773 2025-05-15
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
9 trialsNCT02879162 2025-03-07
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
Phase 2 Completed
NCT02870920 2023-12-08
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02649686 2023-08-04
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
Canadian Cancer Trials Group
Phase 1 Completed
NCT03373760 2023-06-09
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT02766335 2023-05-25
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network
Phase 2/3 Completed
NCT03101475 2022-05-31
ILOC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03102047 2022-04-20
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
NSABP Foundation Inc
Phase 2 Completed